Research

Explore PRISM’s cutting-edge research in omics sciences, bioinformatics, and mass spectrometry, driving breakthroughs in personalized medicine and biological discovery.

Research

The Team

L’unité PRISM (U1192) rassemble une équipe pluridisciplinaire composée de chercheurs, cliniciens, ingénieurs, techniciens et bio-informaticiens, unis par une ambition commune : repousser les frontières de la recherche biomédicale. Grâce à leurs expertises complémentaires en multi-omiques, intelligence artificielle, biologie moléculaire, spectrométrie de masse et vectorisation, ils développent des innovations de rupture.

L’équipe est structurée en plusieurs pôles de compétences, favorisant un dialogue permanent entre sciences fondamentales et applications cliniques. Jeunes chercheurs et experts confirmés travaillent en synergie, soutenus par un environnement propice à l’innovation et à la recherche translationnelle.

PRISM s’inscrit ainsi comme un acteur clé dans le développement de technologies et thérapies innovantes, avec un impact direct sur la médecine personnalisée et la santé publique.

Research

Our Vision and Objectives

At PRISM, we are driven by a bold vision: to revolutionize healthcare by developing cutting-edge technological and therapeutic innovations that address critical clinical challenges. As an interdisciplinary research unit, we bring together experts in mass spectrometry, spatial proteomics, immunotherapy, and biomedical engineering to push the boundaries of medical science.

Our research is structured around two key pillars:

The Technological Innovation– We develop state-of-the-art technologies to explore the complexity of tissues at the molecular level. By combining single-cell and spatial proteomics and minimally invasive surgical tools, we aim to uncover new disease markers and stratify patients for more precise and effective treatments.
The Therapeutic innovations – We translate our discoveries into novel therapies, from next-generation cancer immunotherapies. Our goal is to bring groundbreaking solutions from the lab to the clinic, improving patient care through personalized medicine.

Through strong partnerships with clinical centers such as CLCC Oscar Lambret and CHU Lille, as well as industry collaborations, PRISM is at the forefront of translational research. We are committed to transforming fundamental scientific discoveries into real-world applications, pioneering new diagnostic tools, advanced surgical techniques, and breakthrough immunotherapies.

With a relentless pursuit of innovation, PRISM is shaping the future of biomedical research—where technology meets therapy to redefine patient outcomes.

RESEARCH

Technological innovations

At PRISM, we are developing groundbreaking technologies to push the boundaries of biomedical research and clinical applications. Pillar 1: Technological Innovation is dedicated to creating cutting-edge tools that help us better understand the complexity of the tissue microenvironment and improve surgical and diagnostic techniques. This pillar is structured around two complementary work packages

COSMIX – Unraveling the Tissue Microenvironment

The COSMIX (COmprehensive Spatial Multiomics Investigation of compleX tissues) work package focuses on developing innovative tools to explore the tumor microenvironment at an unprecedented level of detail. By leveraging single-cell and spatial proteomics, we can:

Analyze tissue heterogeneity with high precision, identifying specific cellular populations and molecular signatures.
Develop multi-omics approaches to uncover biomarkers in cancers such as glioblastoma (GBM) and breast cancer (BC).
Integrate mass spectrometry imaging (MSI) and spatial transcriptomics to map disease progression and therapeutic targets.

Through COSMIX, we aim to transform how tumors and their microenvironment are studied, leading to more effective and targeted therapies.

NEXTGENESIS – Revolutionizing Surgery and Diagnosis

The NEXTGENESIS (Next-Generation Surgery and Diagnosis) work package is dedicated to developing state-of-the-art surgical and diagnostic tools to improve patient outcomes. This includes:

SpiderMass – A real-time molecular diagnosis tool that uses laser-based mass spectrometry to assist in minimally invasive surgery, ensuring precise tumor removal.
Snoop-i – A non-invasive breath analysis device that detects cancer-related volatile organic compounds (VOCs) for early disease detection.
Advanced imaging and sensor technologies for large-scale, real-time molecular diagnostics.

By merging high-tech innovations with medical applications, NEXTGENESIS is paving the way for safer surgeries, earlier diagnoses, and improved treatment precision.

Together, COSMIX and NEXTGENESIS embody PRISM’s commitment to technological excellence. By integrating cutting-edge molecular analysis and next-generation surgical tools, Pillar 1 is driving a revolution in precision medicine.

RESEARCH

Therapeutic innovations

At PRISM, we go beyond understanding diseases—we develop innovative therapies to treat them. Pillar 2: Therapeutic Innovations is dedicated to designing and optimizing next-generation treatments, focusing on immunotherapy, personalized medicine, and advanced therapeutic strategies. This pillar is structured around two complementary work packages:

Cutting-Edge 3D Models & Tumor Microenvironment Research

The first work package is focused on creating sophisticated 3D models to revolutionize drug testing and improve cancer treatment strategies. Our objectives include:

Developing complex 3D tissue models that mimic human tumors, enabling preclinical drug testing before moving to animal or human trials.
Investigating the role of nerve fibers in tumor progression, particularly in breast cancer (BC).
Analyzing tumor-derived extracellular vesicles (EVs) and their impact on immune responses and metastasis, with a focus on brain metastases in BC (NEUROCAN project).

By using advanced 3D models, we aim to accelerate drug discovery and improve our understanding of cancer biology, ultimately leading to more effective and personalized treatments.

CARMA & PRODIGY – The Future of Immunotherapy

The second work package is dedicated to developing next-generation immunotherapies that harness the body’s immune system to fight cancer. Our key projects include:

CARMA (Chimeric Antigen Receptor Macrophages) – Developing an innovative CAR-MAC therapy targeting HER2-positive breast cancer patients who have exhausted other treatment options.
PRODIGY – Exploring novel immune checkpoint inhibitors and targeted therapies to enhance the efficacy of existing immunotherapies.
Advancing personalized medicine approaches, including drug repurposing for breast cancer patients in therapeutic impasse.

A major goal for the next five years is to translate these breakthroughs into clinical applications, including first-in-human trials in collaboration with CLCC Oscar Lambret and CHU Lille.

A Unified Vision for Innovation & Patient Care

By combining state-of-the-art 3D modeling with revolutionary immunotherapies, Pillar 2 is redefining how we develop and apply cancer treatments. At PRISM, we are committed to bringing scientific discoveries from the lab to the clinic, offering new hope to patients and shaping the future of precision medicine.